Autism Spectrum Disorder (ASD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Autism Spectrum Disorder (ASD) Market Outlook

Thelansis’s “Autism Spectrum Disorder (ASD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autism Spectrum Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Autism Spectrum Disorder (ASD) Overview

Autism spectrum disorder (ASD) comprises a cluster of neurodevelopmental disorders marked by fundamental deficits across three key domains: social interaction, communication, and repetitive or stereotypical behavior. While the extent of impairment can differ among individuals with ASD, the profound impact on those affected and their families is consistently life-changing. ASD manifests with a broad spectrum of symptom intensity, and each diagnostic category encompasses various functional domains that shape the disorder's effects. Several factors are associated with an increased likelihood of ASD development, including having a sibling with ASD, older parental age, specific genetic conditions (such as Down syndrome or Fragile X syndrome), and very low birth weight. A notable percentage of children with ASD experience a regression in acquired language and social skills before age two. Historically, 40% to 55% of children with autism were diagnosed with mental retardation (MR). ASD affects boys more frequently than girls, with an average male-to-female ratio of 4:1. Different forms of ASD include Autistic Disorder (sometimes referred to as "classical autism"), Childhood Disintegrative Disorder, Pervasive Developmental Disorder, and Asperger Syndrome. The primary approach for treating ASD typically involves behavioral therapy as the first-line intervention, supplemented with pharmacological therapies to enhance daily functioning. Presently, no specific drug therapy is approved for addressing the core symptoms of ASD.

• The estimated prevalence of ASD ranges from 2.47% to 5.2% among children and adolescents in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: